Axonics Inc
NASDAQ:AXNX

Watchlist Manager
Axonics Inc Logo
Axonics Inc
NASDAQ:AXNX
Watchlist
Price: 70.98 USD 0.04% Market Closed
Market Cap: 3.6B USD
Have any thoughts about
Axonics Inc?
Write Note

Intrinsic Value

The intrinsic value of one AXNX stock under the Base Case scenario is 33.81 USD. Compared to the current market price of 70.98 USD, Axonics Inc is Overvalued by 52%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AXNX Intrinsic Value
33.81 USD
Overvaluation 52%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Axonics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for AXNX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about AXNX?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Axonics Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Axonics Inc

Provide an overview of the primary business activities
of Axonics Inc.

What unique competitive advantages
does Axonics Inc hold over its rivals?

What risks and challenges
does Axonics Inc face in the near future?

Has there been any significant insider trading activity
in Axonics Inc recently?

Summarize the latest earnings call
of Axonics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Axonics Inc.

Provide P/S
for Axonics Inc.

Provide P/E
for Axonics Inc.

Provide P/OCF
for Axonics Inc.

Provide P/FCFE
for Axonics Inc.

Provide P/B
for Axonics Inc.

Provide EV/S
for Axonics Inc.

Provide EV/GP
for Axonics Inc.

Provide EV/EBITDA
for Axonics Inc.

Provide EV/EBIT
for Axonics Inc.

Provide EV/OCF
for Axonics Inc.

Provide EV/FCFF
for Axonics Inc.

Provide EV/IC
for Axonics Inc.

Show me price targets
for Axonics Inc made by professional analysts.

What are the Revenue projections
for Axonics Inc?

How accurate were the past Revenue estimates
for Axonics Inc?

What are the Net Income projections
for Axonics Inc?

How accurate were the past Net Income estimates
for Axonics Inc?

What are the EPS projections
for Axonics Inc?

How accurate were the past EPS estimates
for Axonics Inc?

What are the EBIT projections
for Axonics Inc?

How accurate were the past EBIT estimates
for Axonics Inc?

Compare the revenue forecasts
for Axonics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Axonics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Axonics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Axonics Inc compared to its peers.

Compare the P/E ratios
of Axonics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Axonics Inc with its peers.

Analyze the financial leverage
of Axonics Inc compared to its main competitors.

Show all profitability ratios
for Axonics Inc.

Provide ROE
for Axonics Inc.

Provide ROA
for Axonics Inc.

Provide ROIC
for Axonics Inc.

Provide ROCE
for Axonics Inc.

Provide Gross Margin
for Axonics Inc.

Provide Operating Margin
for Axonics Inc.

Provide Net Margin
for Axonics Inc.

Provide FCF Margin
for Axonics Inc.

Show all solvency ratios
for Axonics Inc.

Provide D/E Ratio
for Axonics Inc.

Provide D/A Ratio
for Axonics Inc.

Provide Interest Coverage Ratio
for Axonics Inc.

Provide Altman Z-Score Ratio
for Axonics Inc.

Provide Quick Ratio
for Axonics Inc.

Provide Current Ratio
for Axonics Inc.

Provide Cash Ratio
for Axonics Inc.

What is the historical Revenue growth
over the last 5 years for Axonics Inc?

What is the historical Net Income growth
over the last 5 years for Axonics Inc?

What is the current Free Cash Flow
of Axonics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Axonics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Axonics Inc

Current Assets 525.9m
Cash & Short-Term Investments 345.2m
Receivables 62.6m
Other Current Assets 118m
Non-Current Assets 248.3m
PP&E 41.6m
Intangibles 183m
Other Non-Current Assets 23.7m
Current Liabilities 64.4m
Accounts Payable 20.1m
Accrued Liabilities 44.3m
Non-Current Liabilities 45.3m
Other Non-Current Liabilities 45.3m
Efficiency

Earnings Waterfall
Axonics Inc

Revenue
431.9m USD
Cost of Revenue
-101.1m USD
Gross Profit
330.8m USD
Operating Expenses
-338m USD
Operating Income
-7.2m USD
Other Expenses
1.6m USD
Net Income
-5.7m USD

Free Cash Flow Analysis
Axonics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In the third quarter of 2023, Axonics delivered solid performance with total revenue rising to $93.1 million, a 32% increase over the same period last year. The growth was driven by a 30% rise in sacral neuromodulation (SNM) revenue to $73.9 million, even against a tough comparison from the previous year's third-quarter 42% growth spike, partially driven by high utilization at existing U.S. accounts and new competitive accounts. SNM sales surged nearly 40% internationally, thanks to the impact of a new direct sales force in Australia. Bulkamid revenue soared by 42% to $19.2 million, propelled by increasing reorders and the addition of new accounts. The company's gross margin improved to 74.2% from 72.8%, alongside robust profitability metrics, including $14 million of adjusted EBITDA and nearly $4 million in net income. Looking ahead, full-year revenue guidance has been lifted to $362 million, indicating a 32% growth from the previous year.

What is Earnings Call?
Fundamental Scores

AXNX Profitability Score
Profitability Due Diligence

Axonics Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
ROIC is Increasing
ROE is Increasing
41/100
Profitability
Score

Axonics Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

AXNX Solvency Score
Solvency Due Diligence

Axonics Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
69/100
Solvency
Score

Axonics Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AXNX Price Targets Summary
Axonics Inc

Wall Street analysts forecast AXNX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AXNX is 73.33 USD with a low forecast of 71.71 USD and a high forecast of 78.75 USD.

Lowest
Price Target
71.71 USD
1% Upside
Average
Price Target
73.33 USD
3% Upside
Highest
Price Target
78.75 USD
11% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for AXNX?

Click here to dive deeper.

Dividends

Axonics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for AXNX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

AXNX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

AXNX News

Other Videos

Profile

Axonics Inc Logo
Axonics Inc

Country

United States of America

Industry

Health Care

Market Cap

3.6B USD

Dividend Yield

0%

Description

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. The company is headquartered in Irvine, California and currently employs 517 full-time employees. The company went IPO on 2018-10-31. The company is engaged in developing and commercializing products for patients with bladder and bowel dysfunction. The bladder and bowel dysfunction includes implantable sacral neuromodulation (SNM) systems to treat urinary urge incontinence (UUI) and urinary urgency frequency (UUF), together referred to as overactive bladder (OAB), as well as fecal incontinence (FI), and non-obstructive urinary retention (UR), and a urethral bulking agent to treat female stress urinary incontinence (SUI). The company has designed and developed the rechargeable sacral neuromodulation (SNM) system (r-SNM System), which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company has two relating to its r-SNM System, a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. The company offers urethral bulking agent, Bulkamid for stress urinary incontinence.

Contact

CALIFORNIA
Irvine
26 Technology Dr
+19493966322.0
www.axonics.com

IPO

2018-10-31

Employees

517

Officers

CEO & Director
Mr. Raymond W. Cohen
Chief Financial Officer
Ms. Kari Keese
Chief Operating Officer
Mr. Rinda K. Sama
Executive VP, Chief Marketing & Strategy Officer
Dr. John Woock Ph.D.
Chief Commercial Officer
Mr. Alfred J. Ford Jr.
Chief Technology Officer
Mr. Guangqiang Jiang Ph.D.
Show More
Vice President of Investor Relations
Mr. Neil Bhalodkar
General Counsel & Chief Compliance Officer
Mr. Aaron Pettit
Senior VP, General & IP Counsel
Mr. Michael V. Williamson Esq., J.D.
Chief Medical Officer
Dr. Karen L. Noblett M.A.S., M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one AXNX stock?

The intrinsic value of one AXNX stock under the Base Case scenario is 33.81 USD.

Is AXNX stock undervalued or overvalued?

Compared to the current market price of 70.98 USD, Axonics Inc is Overvalued by 52%.

Back to Top